Literature DB >> 6199457

The reaction of the anti-interferon-alpha monoclonal antibody, NK2, with different interferons.

J T Whittall, R M King, D C Burke.   

Abstract

Analysis of the neutralization of human interferon-alpha by the monoclonal antibody NK2 showed, by three different methods, that the avidity constant was about 10(10)M-1. A small decrease in the avidity constant (and in the antibody titre) with increasing interferon concentrations was observed, suggesting that the antibody-interferon complex had a little biological activity. The antibody neutralizes the interferon by preventing the binding of interferon to susceptible cells. It does not react with human-gamma, mouse-alpha, monkey, bovine or rabbit interferons.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199457     DOI: 10.1099/0022-1317-65-3-629

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor.

Authors:  Y Kawade
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

2.  The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies.

Authors:  Y Kawade; Y Watanabe
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

3.  Immunoradiometric assay of a recombinant human alpha-2 interferon (SCH 30500).

Authors:  W P Protzman; M Minnicozzi; S L Jacobs; D I Surprenant; J Schwartz; E M Oden
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

4.  Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha.

Authors:  P Kontsek; L Borecký; M Novák; E Kontseková; I Máciková
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.